Remarkably, antagonists of Cysltr1, i.e., montelukast or zafirlukast are currently available on the market indicated for the maintenance treatment of asthma, a fact showing that antagonists of Cysltr1 are potential candidates of drug repurposing for a novel indication in HF, which is also supported by other clinical and preclinical studies. Here, CYSLTR1 is linked to asthma.